Intermittent Claudication Associated with Cancer -- Case Studies

Naschitz, Johanan E.; Schechter, Lori; Chang, John B.
September 1987
Angiology;Sep1987, Vol. 38 Issue 9, p696
Academic Journal
Cancer was diagnosed in 15 patients among 300 consecutive patients with intermittent claudication. The cancer-associated claudication is characterized by a more accelerated course of claudication, more often requires vascular surgery, and moreover, the lasting relief of claudication depends upon the efficiency of cancer therapy. It is the authors' impression that cancer-associated claudication is predetermined by atherosclerosis and aggravated by cancer through the chronic hypercoagulability state secondary to neoplasm. The clinical picture Is characterized by rapid progression, with the frequent necessity of vascular surgery for limb salvage and a higher incidence of graft occlusion. Awareness of this possibility of hidden malignancy may be related to the clinical picture of hemodynamic deterioration of the underlying arterial insufficiency. A high index of suspicion leads to earlier diagnosis of neoplasm. Effective oncologic therapy will often bring the symptomatic relief of ischemic symptoms in the lower extremities. This report indicates that associated neoplasm has a more vicious course of the underlying arterial insufficiency and intermittent claudication.


Related Articles

  • Subintimal Angioplasty as a Treatment of Femoropopliteal Artery Occlusions. Veith, Frank J.; Lipsitz, Evan C. // Perspectives in Vascular Surgery & Endovascular Therapy;Jan2004, Vol. 16 Issue 1, p85 

    The authors describe their experience with treating 109 patients with intermittent claudication (78) and critical ischemia (46) by the use of subintimal recanalizations of above-knee femoropopliteal occlusions. Data was entered into a computerized registry and all cases were reviewed....

  • Treatment of intermittent claudication. Karthikeyan, G.; Eikelboom, John W. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;3/21/2009, p671 

    The authors reflect on methods which are used to treat intermittent claudication. They suggest that any methods that are used should improve the patient's symptoms and decrease the risk of cardiovascular problems. They argue that the most important goal of medical treatment in patients with...

  • Methylprednisolone/sodium chloride.  // Reactions Weekly;11/29/2008, Issue 1230, p26 

    The article presents a case study of a 62-year-old man who had a reaction to the administration of methylprednisolone in saline solution. The patient reported leg pain and weakness after the first bolus. The condition returned to baseline after the therapy was discontinued. The condition...

  • Effects of Pentoxifylline on Severe Intermittent Claudication. Reich, Theobald; Gilings, Dennis // Angiology;Sep1987, Vol. 38 Issue 9, p651 

    Pentoxifylline has been shown to improve treadmill walking distances under blinded, controlled conditions in patients with intermittent claudication. From the pooled data of a blinded, controlled, randomized, multicenter trial, the data from all enrolled patients with severe claudication (< 70 m...

  • Comparison of Safety and Efficacy of Buflomedil and Naftidrofuryl in the Treatment of Intermittent Claudication. Rosas, Guillermo; Cerdeyra, Cristina; Lucas, Miguel A.; Parano, Jorge R.; Villa, Juan J. // Angiology;May1981, Vol. 32 Issue 5, p291 

    In a group of 58 patients with peripheral arteriopathies, we have studied efficacy and safety of buflomedil hydrochloride and naftidrofuryl. Both drugs have been shown to have vasoactive properties evaluated through walking capacity and time of hyperemia. According to our results, buflomedil is...

  • Sarpogrelate, a 5-HT2A receptor antagonist in intermittent claudication. A Phase II European study. Norgren, L; Jawien, A; Mátyás, L; Rieger, H; Arita, K; The European MCI-9042 Study Group // Vascular Medicine;2006, Vol. 11 Issue 2, p75 

    This was a multinational, multicentre, double-blind Phase II study in Europe to evaluate the efficacy and safety of two dose regimens (200 mg bid and 200 mg tid) of sarpogrelate (MCI-9042, 5-HT2A receptor antagonist) compared to placebo in patients with stable, moderately severe intermittent...

  • Improvement of Walking Distance in Patients with Intermittent Claudication by Chronic Local Therapy with Isosorbide Dinitrate Ointment. Testa, Roberto; Biagini, Andrea; Michelassi, Claudio; Emdin, Michele; Mazzei, Maria Giovanna; Carpeggiani, Clara; L'Abatte, Antonio // Angiology;Jan1988 Part 1, Vol. 39 Issue 1, p1 

    Isosorbide dinitrate ointment (100 mg tid) was directly applied to 30 male patients with stable, documented intermittent claudication on the areas where ischemic pain was experienced. The symptom-free distance walked (DWA) and the maximum distance reached (MDR) basally, after one, three, six,...

  • Comparative Evaluation of Pentoxifylline, Buflomedil, and Nifedipine in the Treatment of Intermittent Claudication of the Lower Limbs. Chacón-Quevedo, A.; Eguaras, M. G.; Calleja, F.; Garcia, M. A.; Roman, M.; Casares, J.; Muñoz, I.; Concha, M. // Angiology;Jul1994, Vol. 45 Issue 7, p647 

    In the light of the current controversy surrounding the use of hemorheologic and vasodilator drugs in the treatment of peripheral arteriosclerosis, a comparative study was designed in order to evaluate the efficacy of pentoxifylline, buflomedil, and nifedipine in 45 patients with peripheral...

  • Naftidrofuryl: A Review of its Use in the Treatment of Intermittent Claudication. Goldsmith, David R.; Wellington, Keri // Drugs & Aging;2005, Vol. 22 Issue 11, p967 

    Naftidrofuryl (Praxilene®) is a vasodilator that has been used in the treatment of intermittent claudication for >30 years in Europe to improve walking distance and provide symptomatic relief. However, earlier trials had inconsistencies in design and the clinical relevance of the treatment...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics